Alnylam Pharmaceuticals (ALNY) Accumulated Expenses (2009 - 2026)

Alnylam Pharmaceuticals' Accumulated Expenses history runs 18 years deep, the most recent figure standing at $946.5 million for Q1 2026.

• Quarterly Accumulated Expenses rose 34.41% year-over-year to $946.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $946.5 million (up 34.41% YoY) and the FY2025 annual result came in at $1.1 billion, up 36.1% from the prior year.
• Accumulated Expenses was $946.5 million for Q1 2026 at Alnylam Pharmaceuticals, down from $1.1 billion in the prior quarter.
• Across five years, Accumulated Expenses topped out at $1.2 billion in Q3 2025 and bottomed at $355.9 million in Q1 2022.
• A 5-year average of $730.4 million and a median of $713.0 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses jumped 42.89% — and 2025, when it increased 0.76%.
• Alnylam Pharmaceuticals' Accumulated Expenses stood at $545.5 million in 2022, then jumped by 30.72% to $713.0 million in 2023, then rose by 11.32% to $793.7 million in 2024, then surged by 36.1% to $1.1 billion in 2025, then retreated by 12.38% to $946.5 million in 2026.
• Business Quant data shows ALNY's Accumulated Expenses at $946.5 million in Q1 2026, $1.1 billion in Q4 2025, and $1.2 billion in Q3 2025.